Q1 Earnings Estimate for TARS Issued By Lifesci Capital

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) – Lifesci Capital issued their Q1 2026 earnings per share (EPS) estimates for shares of Tarsus Pharmaceuticals in a research note issued on Monday, March 16th. Lifesci Capital analyst F. Brisebois anticipates that the company will earn ($0.52) per share for the quarter. Lifesci Capital has a “Strong-Buy” rating on the stock. The consensus estimate for Tarsus Pharmaceuticals’ current full-year earnings is ($3.17) per share. Lifesci Capital also issued estimates for Tarsus Pharmaceuticals’ Q2 2026 earnings at ($0.36) EPS and FY2026 earnings at ($1.01) EPS.

Several other analysts have also issued reports on TARS. Zacks Research lowered Tarsus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, February 25th. Weiss Ratings restated a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research note on Thursday, January 22nd. Barclays began coverage on shares of Tarsus Pharmaceuticals in a report on Monday, December 8th. They set an “overweight” rating and a $100.00 price objective on the stock. Oppenheimer increased their target price on shares of Tarsus Pharmaceuticals from $95.00 to $105.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 25th. Finally, The Goldman Sachs Group reissued a “neutral” rating and issued a $68.00 price target on shares of Tarsus Pharmaceuticals in a research report on Thursday, February 5th. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $91.83.

Tarsus Pharmaceuticals Trading Down 2.2%

Shares of TARS stock opened at $68.24 on Thursday. The company has a quick ratio of 3.82, a current ratio of 3.85 and a debt-to-equity ratio of 0.21. The firm has a market cap of $2.90 billion, a P/E ratio of -42.12 and a beta of 0.55. The company has a 50 day moving average of $69.59 and a 200-day moving average of $70.20. Tarsus Pharmaceuticals has a 12-month low of $38.51 and a 12-month high of $85.25.

Tarsus Pharmaceuticals (NASDAQ:TARS) last released its earnings results on Monday, February 23rd. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.01). Tarsus Pharmaceuticals had a negative net margin of 14.72% and a negative return on equity of 19.63%. The business had revenue of $151.67 million during the quarter, compared to the consensus estimate of $144.56 million.

Insider Buying and Selling at Tarsus Pharmaceuticals

In related news, Director William J. Phd Link sold 12,500 shares of the business’s stock in a transaction on Monday, March 16th. The stock was sold at an average price of $68.79, for a total transaction of $859,875.00. Following the sale, the director directly owned 116,332 shares in the company, valued at approximately $8,002,478.28. The trade was a 9.70% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Bobak R. Azamian sold 6,000 shares of the firm’s stock in a transaction dated Wednesday, December 24th. The stock was sold at an average price of $82.51, for a total value of $495,060.00. Following the completion of the transaction, the chief executive officer owned 857,991 shares of the company’s stock, valued at approximately $70,792,837.41. This represents a 0.69% decrease in their position. The SEC filing for this sale provides additional information. 8.97% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the company. RTW Investments LP increased its holdings in Tarsus Pharmaceuticals by 5.0% during the 4th quarter. RTW Investments LP now owns 3,335,320 shares of the company’s stock worth $273,096,000 after acquiring an additional 157,884 shares during the period. Deep Track Capital LP lifted its stake in Tarsus Pharmaceuticals by 71.4% in the 3rd quarter. Deep Track Capital LP now owns 3,000,000 shares of the company’s stock worth $178,290,000 after purchasing an additional 1,250,000 shares in the last quarter. Jennison Associates LLC boosted its holdings in Tarsus Pharmaceuticals by 5.5% in the 3rd quarter. Jennison Associates LLC now owns 2,604,580 shares of the company’s stock valued at $154,790,000 after purchasing an additional 136,582 shares during the period. Vanguard Group Inc. boosted its holdings in Tarsus Pharmaceuticals by 5.6% in the 4th quarter. Vanguard Group Inc. now owns 2,399,560 shares of the company’s stock valued at $196,476,000 after purchasing an additional 127,470 shares during the period. Finally, Morgan Stanley grew its position in shares of Tarsus Pharmaceuticals by 6.7% during the 4th quarter. Morgan Stanley now owns 2,040,742 shares of the company’s stock valued at $167,096,000 after purchasing an additional 128,340 shares in the last quarter. 90.01% of the stock is owned by hedge funds and other institutional investors.

More Tarsus Pharmaceuticals News

Here are the key news stories impacting Tarsus Pharmaceuticals this week:

• Positive Sentiment: Lifesci Capital upgraded TARS to a “Strong‑Buy” and published a set of 2026 quarterly and full‑year EPS forecasts that are materially less negative than street consensus — they expect FY2026 EPS of ($1.01) vs. a consensus around ($3.17), and they project a positive Q4 2026 EPS of $0.09. The upgrade and less‑pessimistic FY outlook are supportive for the stock. Lifesci Upgrade / Estimates
• Neutral Sentiment: Analyst consensus still sits at a “Moderate Buy” on TARS, reflecting mixed views across the street — some analysts see upside if clinical/commercial execution improves, while consensus EPS remains negative for the year. Analyst Consensus
• Negative Sentiment: Insider selling: Director William J. Link disclosed a sale of 12,500 shares at an average price of $68.79 on March 16 — a large personal divestiture that may be viewed negatively by some investors as a signal to take profits or reduce exposure. SEC filing: Form 4

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.